Vaxcyte Inc (PCVX) concluded trading on Thursday at a closing price of $33.25, with 0.47 million shares of worth about $15.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.45% during that period and on July 03, 2025 the price saw a loss of about -0.06%. Currently the company’s common shares owned by public are about 128.94M shares, out of which, 125.19M shares are available for trading.
Stock saw a price change of 1.13% in past 5 days and over the past one month there was a price change of -4.04%. Year-to-date (YTD), PCVX shares are showing a performance of -56.78% which decreased to -59.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.66 but also hit the highest price of $121.06 during that period. The average intraday trading volume for Vaxcyte Inc shares is 2.27 million. The stock is currently trading -2.60% below its 20-day simple moving average (SMA20), while that difference is down -0.29% for SMA50 and it goes to -54.28% lower than SMA200.
Vaxcyte Inc (NASDAQ: PCVX) currently have 128.94M outstanding shares and institutions hold larger chunk of about 113.69% of that.
The stock has a current market capitalization of $4.29B and its 3Y-monthly beta is at 1.21. It has posted earnings per share of -$4.07 in the same period. It has Quick Ratio of 17.70 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCVX, volatility over the week remained 4.93% while standing at 4.37% over the month.
Stock’s fiscal year EPS is expected to drop by -24.44% while it is estimated to increase by 5.00% in next year. EPS is likely to grow at an annualized rate of -7.11% for next 5-years, compared to annual growth of -29.88% made by the stock over the past 5-years.
Coverage by Goldman stated Vaxcyte Inc (PCVX) stock as a Buy in their note to investors on December 20, 2024, suggesting a price target of $135 for the stock. Stock get a Buy rating from Needham on January 03, 2023.
